Since the majority of patients with type 2 diabetes mellitus do not lack insulin but rather are resistant to insulin action, agents improving metabolic profile (management of obesity with drugs, including GLP-1 agonists) in addition to drug therapy to control blood glucose are used. The gene discussed is INS; the disease is obesity disorder.